Nexavar fails Phase III trial in breast cancer
This article was originally published in Scrip
Executive Summary
Bayer and Onyx Pharmaceuticals (an Amgen subsidiary) have stumbled in their effort to expand the indications of cancer drug Nexavar (sorafenib) into breast cancer.